Navigation Links
Chimerix To Present At Therapeutic Area Partnerships Meeting
Date:11/26/2012

RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that President and Chief Executive Officer Kenneth I. Moch will present at the 2012 Therapeutic Area Partnerships meeting in Boston, MA.  His presentation will include an update on the company's clinical pipeline, including its lead development compound, CMX001, which was named by conference organizers a "Top 10 Project to Watch in Infectious Diseases." 

Mr. Moch will be presenting on Thursday, November 29 at 3:50 p.m. EST at the Westin Copley Place during the Infectious Diseases Projects to Watch session.  Therapeutic Area Partnerships is regarded as one of the industry's premier biopharmaceutical partnering event.  More information can be found on the meeting's web site:  www.tapartnerships.com.  

About Chimerix
Chimerix is developing novel oral antiviral therapeutics with the potential to improve outcomes for patients in multiple therapeutic areas, including transplant, oncology, acute care and global health. The Company's proprietary lipid technology has given rise to two clinical-stage lipid acyclic nucleoside phosphonates that have demonstrated the potential for enhanced activity and safety compared with currently approved drugs.

Chimerix's lead clinical-stage drug candidate, CMX001, is a novel, broad-spectrum, oral antiviral that inhibits double-stranded DNA (dsDNA) viruses, including cytomegalovirus (CMV), adenovirus (AdV), BK virus and herpes simplex virus. CMX001 has completed Phase 2 clinical development for the prophylaxis of CMV in hematopoietic stem cell transplant (HSCT) recipients and is in Phase 2 development for the preemption and treatment of AdV infection. To date, more than 800 patients have been dosed with CMX001 in controlled clinical trials and open-label treatment protocols. Chimerix has completed an End of Phase 2 meeting with the U.S. Food and Drug Administration and is preparing to initiate Phase 3 clinical development of CMX001 for the prophylaxis of CMV in HSCT recipients in 2013.

In addition to its commercial use, CMX001 is being developed under a contract from the Biomedical Advanced Research and Development Authority (BARDA) as a medical countermeasure to protect against a bioterror threat in the event of a smallpox release.

In July 2012, Chimerix granted an exclusive worldwide license to Merck for the development and commercialization of its second clinical-stage drug candidate, CMX157, for the treatment of HIV infection, further validating the Company's propriety lipid technology.

For more information, please visit www.chimerix.com.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
2. Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
5. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
6. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
7. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
8. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
9. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
10. PRA Expert to Present at Pharmacovigilance Conference
11. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
Breaking Biology Technology:
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):